Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.

Ex Input:
Paragraph: U.S. Bankruptcy Judge Kevin Gross is expected in July to decide whether to halt more than 160 active lawsuits brought by state attorneys general, cities and counties against opioid manufacturer Insys Therapeutics Inc. When it filed for Chapter 11 protection in Delaware earlier this month, Insys requested the cases be paused. A bankruptcy filing would normally halt active litigation immediately, giving a company such as Insys time to reorganize and preserve money that would otherwise be spent fighting the cases. But a longstanding exception in U.S. bankruptcy law can keep the lawsuits alive if they are enforcing government officials’ “police or regulatory power.” The exception holds that government actions seeking to enforce laws related to matters such as public health and safety are not automatically stopped by a company’s bankruptcy filing as other lawsuits are. State and local officials are suing Insys and other drugmakers in an attempt to address harm from an opioid crisis that has killed nearly 400,000 people between 1999 and 2017. More than half these deaths resulted from prescription painkillers, according to the U.S. Centers for Disease Control and Prevention. For a graphic, click tmsnrt.rs/2EgfT0n  “Criminal enterprises … should not be permitted to shield themselves from the consequences of their misconduct by running to bankruptcy court and obtaining the equivalent of a stay that allows them to evade justice,” said Minnesota Attorney General Keith Ellison and Maryland Attorney General Brian Frosh in a Tuesday legal filing opposing Insys’s request to halt lawsuits. The opioid crisis “is a national public health emergency,” they said in the filing, which other state attorneys general supported, including those in New York, New Jersey and Arizona. “The interests of the public therefore are served by allowing these police powers actions of the states to continue unfettered by the injunctions that Insys seeks.”  A spokesman for Insys, which faces trials in Maryland and Minnesota beginning in August, declined to comment beyond the company’s court filings. Insys already had reached a $225 million settlement before filing for bankruptcy with the U.S. Justice Department, admitting to illegal conduct in resolving claims that it bribed doctors to write prescriptions, including medically unnecessary ones, for a fentanyl spray called Subsys designed to treat cancer pain. The Chandler, Arizona-based company still faces, overall, more than 1,000 lawsuits raising similar allegations of deception and fraud in marketing its opioids. The misconduct occurred under a prior management team that has since “entirely turned over” and Insys is now committed to lawful marketing practices, the company said in court papers. Insys contends in bankruptcy-court filings that Judge Gross should halt the lawsuits against it regardless of any exceptions, lest the company drain limited financial resources fighting cases on multiple fronts. Allowing the cases to continue would leave less money for creditors, including the very government officials seeking to hold it to account, Insys contends, adding that its request is not an attempt to escape liability. It had less than $40 million in the bank when filing for bankruptcy and predicts spending up to $9 million through December to continue fighting lawsuits, according to court papers. The judge’s ruling is expected to influence whether another opioid manufacturer facing 2,000 lawsuits - OxyContin maker Purdue Pharma LP - decides to file for bankruptcy protection, according to a person familiar with the matter and legal experts. A Purdue spokesman declined to comment. A ruling allowing the Insys litigation to proceed could discourage Purdue from seeking bankruptcy protection, while pausing the cases might signal that Chapter 11 bankruptcy proceedings are a viable way to halt lawsuits and take advantage of breathing room to reach a broader settlement with plaintiffs, according to the person familiar with the matter and several legal experts. Insys lawyers are attempting to persuade government officials to agree to voluntarily halt their cases, according to a bankruptcy-court filing. Insys is nearing a deal that would effectively halt some of those legal claims against the drugmaker that are consolidated in an Ohio federal court, said Paul Hanly, a lead lawyer for plaintiffs in the opioid litigation. An Insys spokesman declined to comment on the potential agreement. Insys has some legal precedent backing its approach. In 2017, a bankruptcy judge sided with Takata Corp when temporarily halting lawsuits brought by Hawaii, New Mexico and the U.S. Virgin Islands against the Japanese supplier of automobile airbags that exploded, finding that allowing the litigation to continue threatened the company’s reorganization. That would have harmed creditors, including those seeking to hold Takata accountable for widespread deaths and injuries, the judge ruled. The ruling allowed Takata to focus on completing a sale to a rival, creating a combined company called Joyson Safety Systems. A Joyson representative declined to comment. The Minnesota and Maryland attorneys general argued in their legal filing on Tuesday that Insys has not demonstrated the kind of exceptional circumstances present in the Takata case - an unprecedented automotive recall - that warranted halting government lawsuits. While the outcome in the Insys case is not critical for opioid manufacturers with stronger balance sheets that face lawsuits, such as Johnson & Johnson, it holds significance for the likes of OxyContin maker Purdue, according to several legal experts. In March, Reuters reported that Purdue was exploring filing for bankruptcy protection to address lawsuits alleging it pushed prescription painkillers while downplaying their abuse and overdose risks, according to people familiar with the matter. Purdue’s CEO later confirmed the company was considering a bankruptcy filing. The company has denied allegations it contributed to the opioid crisis, pointing to the U.S. Food and Drug Administration approving labels on its drugs carrying warnings about risk and abuse associated with treating pain. Claim: Fate of opioid litigation hinges on government 'police power'.

Ex Output:
2


Ex Input:
Paragraph: Amid warnings from public health officials that a 2020 outbreak of a new coronavirus could soon become a pandemic involving the U.S., alarmed readers asked Snopes to verify a rumor that U.S. President Donald Trump had “fired the entire pandemic response team two years ago and then didn’t replace them.” The claim came from a series of tweets posted by Judd Legum, who runs Popular Information, a newsletter he describes as being about “politics and power.” Legum’s commentary was representative of sharp criticism from Democratic legislators (and some Republicans) that the Trump administration had ill-prepared the country for a pandemic even as one was looming on the horizon. Legum outlined a series of cost-cutting decisions made by the Trump administration in preceding years that had gutted the nation’s infectious disease defense infrastructure. The “pandemic response team” firing claim referred to news accounts from Spring 2018 reporting that White House officials tasked with directing a national response to a pandemic had been ousted. Rear Adm. Timothy Ziemer abruptly departed from his post leading the global health security team on the National Security Council in May 2018 amid a reorganization of the council by then-National Security Advisor John Bolton, and Ziemer’s team was disbanded. Tom Bossert, whom the Washington Post reported “had called for a comprehensive biodefense strategy against pandemics and biological attacks,” had been fired one month prior. It’s thus true that the Trump administration axed the executive branch team responsible for coordinating a response to a pandemic and did not replace it, eliminating Ziemer’s position and reassigning others, although Bolton was the executive at the top of the National Security Council chain of command at the time. Legum stated in a follow-up tweet that “Trump also cut funding for the CDC, forcing the CDC to cancel its efforts to help countries prevent infectious-disease threats from becoming epidemics in 39 of 49 countries in 2018. Among the countries abandoned? China.” That was partly true, according to 2018 news reports stating that funding for the CDC’s global disease outbreak prevention efforts had been reduced by 80%, including funding for the agency’s efforts in China. But that was the result of the anticipated depletion of previously allotted funding, not a direct cut by the Trump administration. And as the CDC told FactCheck.org, the cuts were ultimately avoided because Congress provided other funding. Claim: The Trump administration fired the U.S. pandemic response team in 2018 to cut costs.

Ex Output:
2


Ex Input:
Paragraph: About 1.3 million people worldwide died of TB in 2017. A further 300,000 people with both HIV and TB died in last year, according to World Health Organization figures released this month. Once referred to as ‘consumption’ because of the way sufferers appear to waste away, tuberculosis has been known for centuries. The bacterium responsible for TB was discovered 136 years ago and the development of an effective antibiotic helped rich countries to largely contain the disease after World War II. Still, the U.N. health agency estimates that about 10 million people worldwide become newly infected with TB each year, mostly in poor countries where access to health care is limited. “It really is a global epidemic,” said Dr. Tereza Kasaeva, who heads WHO’s program to combat TB. Speaking ahead of a high-level meeting on the sidelines of the U.N. General Assembly, Kasaeva said the U.N.’s target of eradicating tuberculosis worldwide by 2030 “is very ambitious given that for now progress is too slow.” Like HIV, tuberculosis remains a highly stigmatized illness, preventing some sufferers from seeking treatment. Experts are particularly concerned about the rising number of people contracting drug-resistant variants of TB, many of which aren’t diagnosed properly. Treating them can be costly and arduous, requiring years of medication with strong side effects. Dr. Ralf Otto-Knapp of the German Central Committee to Combat Tuberculosis, a group established in the late 19th century when the disease was still widespread in much of Europe, warned against complacency about the disease in an age of global travel. “Because of the increasing mobility in society it also affects economically more powerful countries,” he said. “We need a joint political will and the necessary resources to fight tuberculosis effectively.” Kasaeva said she hoped leaders attending the New York meeting Wednesday will commit to closing the growing gap between the amount of money available and the billions more required to tackle the disease. Campaigners applauded a recent decision by the World Health Organization to recommend a change in the way drug-resistant tuberculosis is treated, prioritizing oral drugs over injectable medication. The group Doctors Without Borders said such treatment can reduce debilitating side effects, help improve cure rates and cut the number of deaths, but noted that it requires U.S. pharmaceutical giant Johnson & Johnson, which makes the key drug bedaquiline, to reduce its price in low- and middle-income countries with high rates of drug-resistant TB. The company has already sharply reduced costs for the drug in some countries, but in others a six-month course of treatment can cost several thousand dollars — far more than most people can afford. Companies have been reluctant to invest in developing TB medication — with only two new drugs coming onto the market in the past 50 years. Claim: Governments to discuss tackling tuberculosis at UN summit.

Ex Output:

2